SQI Announces Private Placement to Raise CDN $15 Million
/NOT FOR DISSEMINATION IN THE
The agents have been granted an over-allotment option for an additional
The brokered private placement is subject to all necessary regulatory and stock exchange approvals. SQI intends to use the net proceeds principally towards the commercialization of its IgXplex assay and platform development pipeline, working capital for SQiDworks platform placements, expansion of sales and marketing, expansion of manufacturing and general working capital.
The securities being issued in the private placement will be subject to a four-month hold period in accordance with applicable Canadian securities laws. Closing of the brokered private placement will be on or about
About SQI Diagnostics
SQI Diagnostics is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. SQI provides laboratories the ability to simultaneously analyze multiple biomarkers, deliver accurate patient results in less time, significantly reduce labour, and increase profits...All in One Drop. For more information please visit www.sqidiagnostics.com.
Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information: Chief Financial Officer, Andrew Morris, (416) 674-9500 ext. 229, email@example.com; Media and Investor Relations, Adam Peeler, (416) 815-0700 ext. 225, firstname.lastname@example.org